Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Heavy Demand Triggers Shipment Curb for High-Dose Mounjaro Just 1 Month after Launch
July 20, 2023
-
BUSINESS Astellas Becomes 1st Japan Pharma to Sue US Govt over IRA
July 19, 2023
-
REGULATORY Japan’s 1st Stelara, G-Lasta Biosimilars Nearing Finish Line
July 18, 2023
-
BUSINESS Gilead Japan Building Sales Force to Prep for Full Oncology Entry: Chief
July 14, 2023
-
REGULATORY Chuikyo Split over Drug Lags and Losses, Rapid Introduction Evaluation System
July 13, 2023
-
BUSINESS Meiji to Develop Lineup Unaffected by Price Revisions, Bolster Earnings from New Drugs/Generics in Focus Areas
July 12, 2023
-
REGULATORY MHLW Pharma Regulation Panel Kicks Off, Agrees to Discuss Incentives to Develop Pediatric Drugs
July 11, 2023
-
BUSINESS Shionogi to Cut 200 Jobs via Voluntary Buyout Program
July 11, 2023
-
ORGANIZATION Stop Requiring Japanese PI Data for Global Products: JPMA Officials
July 10, 2023
-
REGULATORY PMDA US Office to Set Out Solution for Drug Lag, Loss: Agency Chief
July 10, 2023
-
BUSINESS Full US Nod in Hand, Eisai CEO Keeps 1 Trillion Yen Sales Target for FY2030
July 10, 2023
-
BUSINESS FDA Awards Full Approval to Eisai’s Alzheimer’s Drug
July 7, 2023
-
REGULATORY Pharma Groups Float New Methods to Evaluate Innovative Drugs for 2024 Reform
July 6, 2023
-
REGULATORY Japan, US, Europe Trade Groups Urge Japan to Abolish “Spillover” Re-Pricing
July 6, 2023
-
BUSINESS Insmed Japan to Capitalize on Arikayce, Pins Hopes on Brensocatib: New President
July 5, 2023
-
BUSINESS Alarmed over Domestic Generics Biz, Sawai Group to Review Long-Term Targets
July 5, 2023
-
BUSINESS Jan Stefan Scheld to Helm Nippon Boehringer Ingelheim
July 5, 2023
-
BUSINESS Chugai Is Best-Paying Japan Pharma Again in FY2022, 5 Drug Makers Top 10 Million Yen
July 4, 2023
-
REGULATORY MHLW to Launch Pharma Affairs Study Group July 10, Drug Loss Up for Debate
July 4, 2023
-
REGULATORY LDP Bigwigs Launch Study Group on Drug Discovery to Spur Innovation
July 3, 2023
ページ
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…